XSHE
300534
Market cap450mUSD
Dec 05, Last price
10.49CNY
1D
-0.85%
1Q
3.25%
Jan 2017
-42.45%
IPO
69.98%
Name
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Chart & Performance
P/E
123.31
P/S
3.06
EPS
0.09
Div Yield, %
0.38%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
34.17%
Revenues
1.04b
-3.79%
Net income
26m
-58.14%
CFO
170m
+76.27%
Dividend
Sep 27, 20240.02 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd researches, develops, produces, and sells Chinese medicines, health food, and APIs. It offers Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, and Astragalus Angelica capsules, as well as berberine tannin films. The company also engages in the planting, acquisition, processing, sales, and commercial distribution of Chinese medicinal materials; investment and management of project; and import, sales, logistics, and export of pharmaceutical. Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd was founded in 2002 and is based in Lanzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||